EXPERIENCE OF LOCAL USING OF PLATELET-RICH PLASMA IN 25 PATIENTS WITH DIABETIC FOOT

Petrushenko V.V.1, Grebeniuk D.I.1, Apasova N.V.2

1National Pirogov Memorial Medical University, Vinnytsya (Pirogov str., 56, Vinnytsya, Ukraine, 21018),
2Vinnitsa Regional Clinical Highly Specialized Endocrinology Center (Michurina str., 32, Vinnytsya, Ukraine, 21000)

Annotation. The aim of the study was to evaluate the effectiveness of local using of autologous platelet-rich plasma in the treatment of patients with diabetic foot in stage 2. The study included 25 patients with a diagnosis of diabetic foot in stage 2. At the time of inclusion in the study, all patients had a defect of 3-7 cm² of the skin and subcutaneous adipose tissue in the plantar part of the foot. In addition to the standard treatment, it was decided to perform the local administration of autologous platelet-rich plasma in all patients. The entire platelet-rich plasma volume obtained was injected in the edge of skin around the wound using 30-gauge needles. Repeated injections were performed every 5-7 days until complete healing of the soft tissue defect. To evaluate the effectiveness of the treatment, the area of the ulcerative defect was measured before the manipulation, as well as at an interval of 14 days until the ulcer was completely healed. The following results are obtained: prior to the manipulation, the area of ulcerative defects in the examined population was 511.9±120.3 mm². On the 14th day, this indicator was already 353.6±112.5 mm² and was significantly different from the area of the ulcerative defects before manipulation (p<0.01). On the 28th day, complete healing of diabetic ulcers was observed in 11 (44%) patients, and the area of the skin defect in the study population was 22.4±24.3 mm² and was significantly different from those in all previous study dates (p<0.01). On day 42, we noted the complete healing of ulcers in absolutely all patients. Thus, local injection of an autologous platelet-rich plasma improves the local regenerative process and leads to complete healing of stage 2 diabetic ulcers with an area of 3-7 cm² for 6 weeks.

Keywords: diabetic foot, platelet-rich plasma, reparation.

Introduction

Diabetes mellitus is a metabolic disease with main symptom of hyperglycemia caused by impaired insulin secretion and/or insulin interaction with tissue cells. Chronic hyperglycemia leads to dysfunction of various organs, especially the eyes, kidneys, nerves, heart and blood vessels. The prevalence of ulcerative lesions of the lower extremities caused by diabetes mellitus is estimated to be in the range of 4-10%. In a cohort of patients with diabetic foot, approximately 12-20% of patients need the performing of amputations [1, 4]. In addition to the problem of diabetic angiopathy and neuropathy, attention should be paid to the fact that the condition of patients with diabetic foot may be complicated by the addition of infection, atherosclerosis of peripheral arteries [3].

Long-lasting ulcers are a serious complication in patients with diabetes. Despite active research, diabetes is not amenable to radical treatment, and ulcerative lesions of the foot, which is the most frequent localization of the process, are difficult to treat [2].

Standard treatment of diabetic ulcers includes necrotomy, treatment of the infectious process, mechanical unloading, control of blood glucose levels [1, 4], as well as various methods of local and systemic stimulation of repair [6].

Cell therapy with platelet-rich plasma (PRP) provides a completely new approach to the treatment of diabetic ulcers, which can help avoid limb treatment. PRP is a plasma fraction of autologous blood with a high concentration of platelets. Platelets contain a complete set of coagulation factors, growth and differentiation (insulin-like growth factor, platelet growth factor, transforming growth factor, vascular endothelial growth factor, epidermal growth factor, fibroblast growth factor) in alpha granules, which contribute to the regeneration process. PRP reduces the inflammatory response, activates the function of macrophages and phagocytes in the wound, which leads to neoangiogenesis and epithelialization of the tissue defect [5].

The aim of the study was to evaluate the effectiveness of local using of autologous platelet-rich plasma in the treatment of patients with diabetic foot in stage 2.

Materials and methods

All the procedures were performed according to the ethical standards of the institutional and national research committee, as well as the 1964 Helsinki Declaration and its later changes or comparable ethical standards.

The study was performed at the Department of Endoscopic and Cardiovascular Surgery of National Pirogov Memorial Medical University, Vinnytsya and included 25 patients with a diagnosis of diabetic foot in stage 2. At the time of inclusion in the study, all patients had a defect of the skin and subcutaneous adipose tissue in the plantar part of the foot. The areas of defects were 3-7 cm². All ulcers were not corrected by traditional methods for 2-6 months. All patients lacked any comorbidities that could affect the healing of ulcers. In addition to the standard treatment, it was decided to perform the local administration of autologous PRP in all patients.

PRP was prepared according to the following procedure.
Experience of local using of platelet-rich plasma in 25 patients with diabetic foot

Total volume of 8 ml of blood was sampled from the cubital vein in each patient. PRP was prepared in sterile heparinized plastic test tubes, the heparin content in which was 14-20 U/ml of blood. The blood was centrifuged in a 80-2 centrifuge at a speed of 1500 rpm for 8 minutes, which resulted in about 4.5-5 ml of platelet-rich plasma. As a result of centrifugation, the blood was divided into two layers: the upper layer - platelet-rich plasma, the lower layer - erythrocytes and leukocytes with an insignificant admixture of platelets, which were located in the upper part of the layer. The entire upper layer and about 2 mm of the upper part of the lower layer were taken into a separate sterile syringe.

The entire PRP volume obtained was injected in the edge of skin around the wound using 30-gauge needles. Repeated injections were performed every 5-7 days until complete healing of the soft tissue defect.

To evaluate the effectiveness of the treatment, the area of the ulcerative defect was measured before the manipulation, as well as at an interval of 14 days until the ulcer was completely healed.

The obtained data were processed using the statistical software package SPSS 20.0 for Windows.

**Results. Discussion**

Prior to the manipulation, the area of ulcerative defects in the examined population was 511.9±120.3 mm². On the 14th day, this indicator was already 353.6±112.5 mm² and was significantly different from the area of the ulcerative defects before manipulation (p<0.01). On the 28th day, complete healing of diabetic ulcers was observed in 11 (44%) patients, and the area of the skin defect in the study population was 22.4±24.3 mm² and was significantly different from those in all previous study dates (p<0.01). On day 42, we noted the complete healing of ulcers in absolutely all patients.

The dynamics of the healing of diabetic ulcers is shown in Figure 1.

The gold standard for treating diabetic ulcers is the treatment of an ulcer, infection control, revascularization, and stimulation of repair. Other advanced methods have also been proposed as adjuvant therapies, such as hyperbaric oxygen therapy, VAC therapy. However, at the moment, insufficient data have been collected regarding their clinical and cost-effectiveness in the treatment of the diabetic foot [2].

**Conclusions and prospects for further research**

1. Local injection of an autologous platelet-rich plasma improves the local regenerative process and leads to complete healing of stage 2 diabetic ulcers with an area of 3-7 cm² for 6 weeks.

In the future, it is planned to continue the collection of clinical material, its statistical processing and critical analysis.

**References**

1. Abredari, H., Bolouchifard, F., Rassouli, M., Nasiri, N., Taher, M. & Abedi, A. (2015). Health locus of control and self-care behaviors in diabetic foot patients. *Med. J. Islam. Repub. Iran*, 29, 283. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4764266/.
2. Andrews, K. L., Houdek, M. T. & Kiemele, L. J. (2015). Wound management of chronic diabetic foot ulcers: from the basics to regenerative medicine. *Prosthet Orthot. Int.*, 39 (1), 29-39. DOI: 10.1177/0309366614534296.
3. Hicks, C. W., Selvarajah, S., Mathioudakis, N., Sherman, R. E., Hines, K. F., Black, J. H. 3rd & Abularrage, C. J. (2016). Burden of Infected Diabetic Foot Ulcers on Hospital Admissions and Costs. *Ann. Vasc. Surg.*, 33, 149-158. DOI: 10.1016/j.avsg.2015.11.025.
4. Kadam, D. (2016). Microsurgical Reconstruction of Plantar Ulcers of the Insensate Foot. *J. Reconstr. Microsurg.*, 32 (5), 402-410. doi:10.1055/s-0036-1579536.
5. Picard, F., Hersant, B., Bosc, R. & Meningaud, J. P. (2015). The growing evidence for the use of platelet-rich plasma on diabetic chronic wounds: A review and a proposal for a new standard care. *Wound Repair Regen.*, 23 (5), 638-643. DOI: 10.1111/wrr.12317.
6. Zhang, Z. & Lv, L. (2016). Effect of local insulin injection on wound vascularization in patients with diabetic foot ulcer. *Exp. Ther. Med.*, 11 (2), 397-402.
ДОСВІД ЛОКАЛЬНОГО ЗАСТОСУВАННЯ ПЛАЗМИ, ЗБАГАЧЕНОЇ ТРОМБОЦИТАМИ, У 25 ПАЦІЄНТІВ ІЗ ДІАГНОЗОМ ДІАБЕТИЧНОЇ СТОПИ

Петрушенко В.В., Гребенюк Д.И., Апасова Н.В.

Анотація. Цільою дослідження було оцінити ефективність локального застосування аутологічної плазми збагаченої тромбоцитами в лікуванні пацієнтів з діабетичною стадією 2. В дослідження були включени 25 пацієнтів із діагнозом діабетичної стопи в стадії 2. На момент включення в дослідження всі пацієнти мали дефекти шкіри та підшкірної жирової клітинки в ділянці підошвої частини стопи площею 3-7 см². В допомогу до стандартного лікування було вирішено провести місцеве введення аутологічної плазми збагаченої тромбоцитами всім пацієнтам. Всього отриманий об’єм плазми, збагаченої тромбоцитами, вводили в край шкіри навколо ранці за допомогою голок 30-го калібру. Повторні ін’єкції проводили кожні 5-7 днів до повного зазнечення дефекту щиткових тканин. Для оцінки ефективності лікування площу виразкового дефекту вимірювали до маніпуляцій, а також з інтервалом в 14 днів до повного зазнечення виразки. Отримані наступні результати: до інтервалу площу виразкових дефектів у досліджуваному контингенті становила 511,9±120,3 мм², на 14-й день цей показник вже становив 353,6±112,5 мм² та достовірно відрізнявся від площі виразкових дефектів до маніпуляції (р<0,01). На 28-й день подібний результат був частіше спостерігатися у 11 (44%) пацієнтів, а площа дефекту шкіри в досліджуваному контингенті становила 22,4±24,3 мм² та значно відрізнялася від такої на всіх попередніх термінах дослідження (р<0,01). На 42 день було відміщено повне зазнечення виразкових дефектів абсолютно у всіх пацієнтів. Таким чином, локальне введення аутологічної плазми, збагаченої тромбоцитами, покращує місцевий регенеративний процес і призводить до повного зазнечення виразкових дефектів у стадії 2 площею 3-7 см² протягом 6 тижнів.

Ключові слова: діабетична стопа, плазма, збагачення тромбоцитами, репарація.

ОПІЙ ЛОКАЛЬНОГО ПРИМЕНЕНИЯ ПЛАЗМЫ, ОБОГАЩЕННОЙ ТРОМБОЦИТАМИ, У 25 ПАЦІЄНТОВ С ДІАГНОЗОМ ДІАБЕТИЧЕСКОЙ СТОПЫ

Петрушенко В.В., Гребенюк Д.И., Апасова Н.В.

Аннотация. Целью исследования было оценить эффективность локального применения аутологичной плазмы, обогащенной тромбоцитами, в лечении пациентов с диабетической стадией 2. В исследование были включены 25 пациентов с диагнозом диабетической стопы в стадии 2. На момент включения в исследование все пациенты имели дефект кожи и подкожной жировой клетчатки в области подошвенной части стопы площадью 3-7 см². В дополнение к стандартному лечению было решено провести местное введение аутологичной плазмы, обогащенной тромбоцитами, всем пациентам. Всего полученный объем плазмы, обогащенной тромбоцитами, вводили в край кожи вокруг раны с помощью игл 30-го калибра. Повторные инъекции проводили каждые 5-7 дней до полного заживления дефекта мягких тканей. Для оценки эффективности лечения площадь язвенного дефекта измеряли до манипуляции, а также с интервалом в 14 дней до полного заживления язвы. Получены следующие результаты: до манипуляции площадь язвенных дефектов в исследуемом контингенте составляла 511,9±120,3 мм². На 14-й день этот показатель уже составлял 353,6±112,5 мм² и достоверно отличался от площади язвенных дефектов до манипуляции (р<0,01). На 28-й день полное заживление диабетических язв наблюдалось у 11 (44%) пациентов, а площадь дефекта кожи в исследуемом контингенте составляла 22,4±24,3 мм² и значительно отличалась от таковой на всех предыдущих терминах исследования (р<0,01). На 42 день было отмечено полное заживление язвенных дефектов абсолютно у всех пациентов. Таким образом, локальное введение аутологичной плазмы, обогащенной тромбоцитами, улучшает местный регенеративный процесс и приводит к полному заживлению диабетических язв в стадии 2 площадью 3-7 см² на протяжении 6 недель.

Ключевые слова: диабетическая стопа, плазма, обогащённая тромбоцитами, репаразия.